Rosai-Dorfman病的诊治进展

doi:10.16352/j.issn.1001-6325.2022.11.1785

基础医学与临床 ›› 2022, Vol. 42 ›› Issue (11): 1785-1790.doi: 10.16352/j.issn.1001-6325.2022.11.1785

Rosai-Dorfman病的诊治进展

刘婷, 曹欣欣^*

中国医学科学院北京协和医学院北京协和医院血液内科, 北京 100730

收稿日期:2021-08-06 修回日期:2021-12-08 出版日期:2022-11-05 发布日期:2022-11-01
通讯作者: ^* caoxinxin@pumch.cn
基金资助:
北京市自然科学基金(7202160); 中国医学科学院基本科研业务费健康长寿项目(2019-RC-HL-001)

Progress in the diagnosis and treatment of Rosai-Dorfman disease

LIU Ting, CAO Xin-xin^*

Department of Hematology, Peking Union Medical College Hospital, CAMS & PUMC, Beijing 100730, China

Received:2021-08-06 Revised:2021-12-08 Online:2022-11-05 Published:2022-11-01
Contact: ^* caoxinxin@pumch.cn

摘要/Abstract

摘要： 罗道病(RDD)是一种罕见的非朗格汉斯细胞组织细胞增生症,其病因及发病机制尚未完全阐明,临床表现具有高度异质性, 极易误诊、漏诊,目前尚无统一的治疗方法。本文通过文献回顾,就近年来有关RDD的发病机制、诊断和治疗进展进行综述,并总结了RDD的治疗原则。RDD的治疗需个体化,对于单纯淋巴结型或仅皮肤受累的无症状RDD患者,可先予观察,密切随诊;对于结外孤立性病灶或造成局部器官压迫的RDD患者,建议手术切除病灶;对于全身性及复发难治性RDD患者,可考虑全身药物治疗。

关键词: Rosai-Dorfman病, 临床表现, 治疗

Abstract: Rosai-Dorfman disease (RDD) is a rare non-Langerhans cell histiocytosis. Its etiology and pathogenesis are yet incompletely elucidated. The clinical manifestations of RDD are highly heterogeneous. It is easy to be misdiagnosed or missed diagnosis. There is no standard treatment at present. Therefore, the progression in pathogenesis, diagnosis and treatment are reviewed. The treatment of RDD is best tailored to the individual clinical circumstances. Observation is suitable for patients with uncomplicated lymphadenopathy or asymptomatic cutaneous RDD. For RDD patients with extra nodal unifocal disease or organ compression, surgery is recommended. Systemic therapy can be considered for patients with systemic, recurrent or refractory RDD.

Key words: Rosai-Dorfman disease, clinical manifestations, treatment

中图分类号:

R559

刘婷, 曹欣欣. Rosai-Dorfman病的诊治进展[J]. 基础医学与临床, 2022, 42(11): 1785-1790.

LIU Ting, CAO Xin-xin. Progress in the diagnosis and treatment of Rosai-Dorfman disease[J]. Basic & Clinical Medicine, 2022, 42(11): 1785-1790.

参考文献 26

[1]	Mahzoni P, Zavareh MHT, Bagheri M, et al. Intracranial Rosai-Dorfman disease[J]. J Res Med Sci, 2012, 17: 304-307.
[2]	Garces S, Medeiros LJ, Patel KP, et al. Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai-Dorfman disease[J]. Mod Pathol, 2017, 30: 1367-1377.
[3]	Levine PH, Jahan N, Murari P, et al. Detection of human herpesvirus 6 in tissues involved by sinus histiocytosis with massive lymphadenopathy(Rosai-Dorfman disease)[J]. J Infect Dis, 1992, 166: 291-295.
[4]	Diamond EL, Durham BH, Haroche J, et al. Diverse and targetable kinase alterations drive histiocytic neoplasms[J]. Cancer Discov, 2016, 6: 154-165.
[5]	Durham BH, Lopez Rodrigo E, Picarsic J, et al. Activat-ing mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms[J]. Nat Med, 2019, 25: 1839-1842.
[6]	Fatobene G, Haroche J, Hélias-Rodzwicz Z, et al. BRAF V600E mutation detected in a case of Rosai-Dorfman disease[J].Haematologica,2018, 103: e377-e379.
[7]	Chen J, Zhao AL, Duan MH, et al. Diverse kinase alterations and myeloid-associated mutations in adult histiocytosis[J].Leukemia,2021.doi: 10.1038/s41375-021-01439-3.
[8]	Abla O, Jacobsen E, Picarsic J, et al. Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease[J]. Blood, 2018, 131: 2877-2890.
[9]	Foucar E, Rosai J, Dorfman R. Sinus histiocytosis with massive lymphadenopathy(Rosai-Dorfman disease): review of the entity[J]. Semin Diagn Pathol, 1990, 7: 19-73.
[10]	Sandoval-Sus JD, Sandoval-Leon AC, Chapman JR, et al. Rosai-Dorfman disease of the central nervous system: report of 6 cases and review of the literature[J]. Medicine(Baltimore), 2014, 93: 165-175.
[11]	刘旭, 胡余昌, 唐立华. Rosai-Dorfman病研究进展[J]. 中华病理学杂志,2017, 46: 443-446.
[12]	Emile JF, Abla O, Fraitag S, et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages[J]. Blood, 2016, 127: 2672-2681.
[13]	Goyal G, Ravindran A, Young JR, et al. Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease[J]. Haematologica, 2020, 105: 348-357.
[14]	Pulsoni A, Anghel G, Falcucci P, et al. Treatment of sinus histiocytosis with massive lymphadenopathy(Rosai-Dorfman disease): report of a case and literature review[J]. Am J Hematol, 2002, 69: 67-71.
[15]	Lima FB, Barcelos PS, Constâncio APN, et al. Rosai-Dorfman disease with spontaneous resolution: case report of a child[J]. Rev Bras Hematol Hemoter, 2011, 33: 312-314.
[16]	Al-Khateeb THH. Cutaneous Rosai-Dorfman disease of the face: a comprehensive literature review and case report[J]. J Oral Maxillofac Surg, 2016, 74: 528-540.
[17]	Forest F, N'Guyen AT, Fesselet J, et al. Meningeal Rosai-Dorfman disease mimicking meningioma[J]. Ann Hematol, 2014, 93: 937-940.
[18]	Cooper SL, Arceci RJ, Gamper CJ, et al. Successful treatment of recurrent autoimmune cytopenias in the context of sinus histiocytosis with massive lymphadeno-pathy using sirolimus[J]. Pediatr Blood Cancer, 2016, 63: 358-360.
[19]	Wang W, Sun J, Zhang W, et al. Successful treatment of intracranial Rosai-Dorfman disease with cytarabine and dexamethasone: case report and review of literature[J]. Ann Hematol, 2020, 99: 1157-1159.
[20]	Simko SJ, Tran HD, Jones J, et al. Clofarabine salvage therapy in refractory multifocal histiocytic disorders, including Langerhans cell histiocytosis, juvenile xanthogranuloma and Rosai-Dorfman disease[J]. Pediatr Blood Cancer, 2014, 61: 479-487.
[21]	Chen E, Pavlidakey P, Sami N. Rosai-Dorfman disease successfully treated with thalidomide[J]. JAAD Case Rep, 2016, 2: 369-372.
[22]	Rubinstein M, Assal A, Scherba M, et al. Lenalidomide in the treatment of Rosai Dorfman disease—a first in use report[J]. Am J Hematology, 2016, 91: E1.doi:10.1002/ajh.24225.
[23]	Jacobsen E, Shanmugam V, Jagannathan J. Rosai-Dorf-man disease with activating KRAS mutation-response to cobimetinib[J]. N Eng J Medicine, 2017, 377: 2398-2399.
[24]	Moyon Q, Boussouar S, Maksud P, et al. Lung involvement in Destombes-Rosai-Dorfman disease: clinical and radiological features and response to the MEK inhibitor cobimetinib[J]. Chest, 2020, 157: 323-333.
[25]	Giuffrè C, Giuffrè G. Choroidal involvement in Rosai-Dorfman disease successfully treated with cobimetinib[J]. Indian J Ophthalmol, 2020, 68: 2051-2053.
[26]	Mastropolo R, Close A, Allen S W, et al.BRAF-V600E-mutated Rosai-Dorfman-Destombes disease and Langer-hans cell histiocytosis with response to BRAF inhibitor[J]. Blood Adv, 2019, 3: 1848-1853.

Rosai-Dorfman病的诊治进展

Progress in the diagnosis and treatment of Rosai-Dorfman disease

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 26

相关文章 15

编辑推荐

Metrics

本文评价

[1]	夏雨佳, 杨振丽, 刘玉琴. 肿瘤类器官临床前转化研究及应用[J]. 基础医学与临床, 2024, 44(9): 1214-1218.
[2]	王靓, 夏隆阔, 张建民. 脑类器官在药物研发中的研究进展[J]. 基础医学与临床, 2024, 44(9): 1208-1213.
[3]	刘保清, 黄容, 卢艳, 李凯, 张宁, 刘长征, 宋伟. 胃癌类器官在基础研究与临床应用中的进展[J]. 基础医学与临床, 2024, 44(9): 1219-1222.
[4]	彭晴怡, 许岭翎. 1型糖尿病诱发肌少症的研究进展[J]. 基础医学与临床, 2024, 44(8): 1189-1193.
[5]	韩迎东, 王嵩, 张昀, 曾学军. 嗜酸性粒细胞增多综合征合并外周动脉栓塞患者的临床特点分析[J]. 基础医学与临床, 2024, 44(8): 1157-1161.
[6]	高艺丹, 蒋雪涵, 张红, 杨沛然. 靶向异常通路的动脉性肺动脉高压新型药物研发[J]. 基础医学与临床, 2024, 44(8): 1088-1093.
[7]	付志刚, 覃佳, 谭江山. 门脉高压性肺动脉高压:诊治进展与挑战[J]. 基础医学与临床, 2024, 44(8): 1068-1073.
[8]	李阳, 朱蕾. 真核延伸因子2激酶是治疗肿瘤的潜在新靶标[J]. 基础医学与临床, 2024, 44(7): 1039-1043.
[9]	段然, 李青原, 冯同. 代谢重编程在特发性肺纤维化发病中的作用[J]. 基础医学与临床, 2024, 44(6): 882-886.
[10]	中国老年保健协会生长发育和性腺疾病分会. 儿童和青少年颅咽管瘤术后内分泌管理专家共识[J]. 基础医学与临床, 2024, 44(5): 585-598.
[11]	高晓倩, 于华惠, 刘圣, 焦晓璐, 吕倩雯, 张铭, 秦彦文. 血尿素氮水平对急性冠状动脉综合征患者PCI术后MACE的预测价值[J]. 基础医学与临床, 2024, 44(5): 606-612.
[12]	傅晨, 李平. 重型再生障碍性贫血治疗的研究进展[J]. 基础医学与临床, 2024, 44(5): 719-723.
[13]	张沥元, 杜函泽, 潘慧. 治疗下丘脑性肥胖的药物研究进展[J]. 基础医学与临床, 2024, 44(5): 729-732.
[14]	刘宛榕, 赵林. 颅内生殖细胞肿瘤的药物治疗[J]. 基础医学与临床, 2024, 44(10): 1350-1356.
[15]	葛郁平, 刘莹, 赵林. 血管肉瘤药物治疗进展[J]. 基础医学与临床, 2024, 44(10): 1363-1367.